InvestmentJun 25, 2026, 06:36 AM
ProQR Raises $59.2M in Share Offering & Private Placement
AI Summary
ProQR Therapeutics N.V. announced the pricing of a registered direct offering of 27,624,310 ordinary shares at $1.81 per share, aiming to raise approximately $50.0 million. Concurrently, Eli Lilly and Company, an existing shareholder and strategic partner, agreed to purchase 5,100,780 ordinary shares at the same price in a private placement, generating an additional $9.2 million. The total gross proceeds of approximately $59.2 million are intended to fund research and clinical development of pipeline candidates, as well as for working capital and general corporate purposes.
Key Highlights
- ProQR priced a registered direct offering of 27,624,310 ordinary shares at $1.81 per share.
- The offering is expected to generate approximately $50.0 million in gross proceeds.
- Eli Lilly and Company agreed to purchase 5,100,780 ordinary shares at $1.81 per share in a concurrent private placement.
- The private placement with Lilly is expected to generate approximately $9.2 million in gross proceeds.
- Total gross proceeds from both transactions are approximately $59.2 million.
- Proceeds will primarily fund research and clinical development of pipeline candidates.
- BofA Securities, Evercore ISI, and Cantor are joint lead bookrunning managers for the offering.
Price Impact
More from PRQR